NCT07183306View on ClinicalTrials.gov

A Clinical Study of HT-101 and/or HT-102 in Patients With Chronic Hepatitis B Virus Infection

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

December 30, 2024

Primary Completion Date

August 24, 2026

Study Completion Date

May 3, 2027

Conditions
Chronic Hepatitis B
Interventions
DRUG

HT-101

HT-101 given by subcutaneous injection.

DRUG

HT-102

HT-102 given by subcutaneous injection.

Trial Locations (7)

100015

Beijing Ditan Hospital Capital Medical University, Beijing

200083

Shanghai Public Health Clinical Center, Shanghai

361001

Xiamen Hospital of Traditional Chinese Medicine, Xiamen

510440

Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou

510515

Nanfang Hospital, Guangzhou

511518

Qingyuan People's Hospital, Qingyuan

610072

Sichuan Provincial People's Hospital, Chengdu

All Listed Sponsors
lead

Suzhou HepaThera Biotech Co., Ltd.

INDUSTRY

NCT07183306 - A Clinical Study of HT-101 and/or HT-102 in Patients With Chronic Hepatitis B Virus Infection | Biotech Hunter | Biotech Hunter